Team Praesidia
We have come together with the overarching goal of improving the therapeutic outcome of drugs for patients
Leadership Team
Praesidia is a culmination of the two founders’ over 50 years of combined drug development experience and 25 years of entrepreneurial track record punctuated by 2 successful exits. The breadth of drug development experience encompasses new target identification and new drug discovery, recombinant protein and monoclonal antibody design, as well as platform development. The R&D experience covers the complete drug development lifecycle: from high expression cell lines to process/ CMC development to scaling up to large scale GMP Manufacturing for clinical studies and market.
The Founders’ experience and expertise have been exponentially enriched by an expanding panel of eminent Advisors with prominent academic, industrial and clinical pedigrees.
Board
Management
Advisors
Eugene Sullivan, MD
Regulatory Consultant
Rita Balice-Gordon, Ph.D
Strategic Advisor
Scientific Advisors
Dr. Rey Panettieri, MD
Vice Chancellor for Translational Medicine and Science Director, Rutgers Institute for Translational Medicine and Science Professor of Medicine, Robert Wood Johnson Medical School Emeritus Professor of Medicine, University of Pennsylvania
Dr. Frank McCormack, MD
Professor of Internal Medicine &
Director of pulmonary critical care
University of Cincinnati College of Medicine
Dr. Alexis M Demopoulos, MD
Department of Neuro-oncology, Neurology. Northwell Health, NYC
Fabio M. Iwamoto, MD
Department of Neurology, Columbia University, NYC